Multidrug-Resistant Bacteria Market research report by The Business Research Company offers information on global market size, growth rate, regional shares, competitive analysis, detailed segments, trends and opportunities.
How big is the global market for multidrug-resistant bacteria?
The multidrug-resistant bacteria market is expected to grow strongly in the next few years, reaching $16.22 billion by 2028, a compound annual growth rate (CAGR) of 6.5%.
The growth during the forecast period is attributed to antibiotic stewardship programs, global spread of resistance, phage therapy and alternative treatment methods, and public and private investments. The key trends during the forecast period include precision medicine for infectious diseases, combination therapies, continuous surveillance and control, and global collaboration.
Top companies in the multi-resistant bacteria market
Major players in the multidrug-resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd. and Merck And Co.
Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Dr. Reddy's Laboratories Ltd., Lupine Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc ., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.
Pre-order your research report today and get it delivered quickly:
www.thebusinessresearchcompany.com/purchas…x?id=13044
Market drivers and trends for multi-resistant bacteria with examples
The market for multidrug-resistant bacteria is growing as the prevalence of infectious diseases increases. Multidrug-resistant bacteria pose a major challenge due to their resistance to multiple antibiotics.
The data show a significant increase in notifiable infectious diseases and underline the urgent need for effective treatments.
This growing problem is driving the market for solutions to combat resistant bacterial strains.
Multi-resistant bacteria market segmentation
The multi-drug resistant bacteria market covered in this report is segmented –
1) After illness: Urinary tract infection; Intra-abdominal infections; Bloodstream infections; Clostridium difficile infections; Acute bacterial skin and skin structure infections; Hospital-acquired bacterial pneumonia; Acquired bacterial pneumonia; Other diseases
2) By drug class: Oxazolidinones; Lipoglycopeptides; Tetracyclines; Cephalosporins; Combination therapies; Other drug classes
3) By route of administration: Oral; Parenteral; Other routes of administration
4) By end user: Hospitals; Specialized clinics; Home care; Other end users
Table of contents
1.Introduction
• Overview of the multi-resistant bacteria market
• Comprehensive analysis of the multi-drug resistant bacteria market
2. Drivers and barriers in the multi-drug resistant bacteria market
• Drivers and constraints for the historical and forecast period
3. Market segmentation for multi-resistant bacteria
• After illness
• By drug class
• By route of administration
• By end user
4.Competitive landscape and company profiles in the multi-drug resistant bacteria market
• Overview
• Products and services
• Strategy
5. Regional and country-specific analysis of the multi-drug resistant bacteria market
• By region
• By country
6.Market trends and opportunities in the multi-drug resistant bacteria market
• Technological advances
• New trends
7. Market prospects and potential analysis for multi-resistant bacteria
• Growth strategies
• New opportunities
Make informed decisions with our comprehensive market reports. Get your free sample now!
www.thebusinessresearchcompany.com/sample.…p;type=smp
Multidrug-resistant bacteria are strains of bacteria that have developed resistance to multiple types or classes of antibiotics. These bacteria are no longer sensitive to the effects of different antibiotics that would normally be effective in treating bacterial infections.
Multi-resistant germs often occur in hospitals and medical facilities when antibiotics are used longer than necessary or unnecessarily.
News from
Category: Industry reports and market analyses Profile: The Business Research Company is a leading provider of market research and consulting services. The company offers over 9,500 market reports covering 27 industries in over 60 geographies, delivering detailed insights and forecasts. Its customized research solutions help companies make critical decisions, while its continuous research service enhances organizational capabilities. Its leading database Global Market Model offers comprehensive market intelligence with 1,500,000 records covering over 8,000 market segments. …
This email address is protected from spambots. JavaScript must be enabled to view it!
